C4 Therapeutics (CCCC) Change in Receivables (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Change in Receivables of $482000.0 for Q1 2026, down 90.22% year-over-year from $4.9 million in Q1 2025, and up 111.64% quarter-over-quarter from -$4.1 million in Q4 2025.
C4 Therapeutics (CCCC) Change in Receivables (2019 - 2026) Analysis & Trends
C4 Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at $482000.0 for Q1 2026.
- In Q1 2026, Change in Receivables fell 90.22% year-over-year to $482000.0; the TTM figure through Mar 2026 stood at -$5.1 million (up 7.63% YoY), while the FY2025 annual figure was -$701000.0, up 91.94% from the prior year.
- Change in Receivables for Q1 2026 stood at $482000.0, up from -$4.1 million in the prior quarter.
- The five-year high for Change in Receivables was $11.3 million in Q4 2023, with the low at -$12.4 million in Q2 2024.
- The 5-year median for Change in Receivables is -$63000.0 (2022), against an average of -$166647.1.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables surged 75433.33% in 2023, then plunged 2586.2% in 2024.
- C4 Therapeutics' Change in Receivables stood at -$15000.0 in 2022, then soared by 75433.33% to $11.3 million in 2023, then tumbled by 164.06% to -$7.2 million in 2024, then jumped by 42.8% to -$4.1 million in 2025, then surged by 111.64% to $482000.0 in 2026.
- Business Quant data shows CCCC's Change in Receivables at $482000.0 in Q1 2026, -$4.1 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | -1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.55 Mn |
| Jun 30, 2026 | -1.55 Mn |
| Mar 31, 2026 | 482,000.00 |
| Mar 31, 2026 | 482,000.00 |
| Dec 31, 2025 | -4.14 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Jun 30, 2025 | -5.83 Mn |
| Jun 30, 2025 | -5.83 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Dec 31, 2024 | -7.24 Mn |
| Sep 30, 2024 | 9.17 Mn |
| Sep 30, 2024 | 9.17 Mn |
| Jun 30, 2024 | -12.43 Mn |
| Jun 30, 2024 | -12.43 Mn |
| Mar 31, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.80 Mn |